New antibody BT02 takes on Hard-to-Treat blood cancers
NCT ID NCT07107204
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tests a new drug called BT02, a monoclonal antibody, in 116 adults with relapsed or refractory blood cancers like leukemia, lymphoma, or multiple myeloma. Participants receive the drug by IV every 2-3 weeks for up to two years. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BT02 (a monoclonal antibody given by IV every 2-3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with blood cancers that have stopped responding to standard therapy.
What could go wrong
This is a very early, small trial (Phase 1/2) focused on safety and dosing, so it is far from proving effectiveness. The drug may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••